Denver-based SeaStar is developing a platform therapy focused on hyperinflammation of vital organs. The company’s Selective Cytopheretic Device was designated as a breakthrough device by the FDA earlier this year.
SeaStar is set to go public in the third quarter of 2022 through a combination with special purpose acquisition company (SPAC) LMF Acquisition Opportunities (Nasdaq: LMAO).
Get the full story at our sister site, Medical Design & Outsourcing.
Dr. Kevin Chung will be the chief medical officer of SeaStar Medical. [Photo courtesy of SeaStar Medical]
SeaStar Medical has hired Dr. Kevin Chung as chief medical officer of the medtech developer starting July 1.Denver-based SeaStar is developing a platform therapy focused on hyperinflammation of vital organs. The company’s Selective Cytopheretic Device was designated as a breakthrough device by the FDA earlier this year.
SeaStar is set to go public in the third quarter of 2022 through a combination with special purpose acquisition company (SPAC) LMF Acquisition Opportunities (Nasdaq: LMAO).
“Dr. Chung’s decades of practical experience with known applications of extracorporeal therapies and his service as a critical care intensivist make him uniquely positioned to lead SeaStar Medical’s clinical development programs,” SeaStar President and CEO Eric Schlorff said in a news release. “We are…
New York-based Synchron said this study demonstrated the safety of its brain-computer interface (BCI) technology. The device is delivered by catheter rather than the open-brain surgeries used by other neurotech developers like Elon Musk’s Neuralink.
Get the full story at our sister site, Medical Design & Outsourcing.
Synchron’s Stentrode device expands inside a blood vessel on the brain to relay motor signals [Illustration courtesy of Synchron]
Four ALS patients with a Synchron Stentrode brain implant had no serious adverse events one year after their procedure, which allowed the paralyzed patients to control a computer for online shopping, banking and text communication without using their hands or voice for input.New York-based Synchron said the study — allowed by the FDA under an Investigational Device Exemption — demonstrated the safety of its brain-computer interface (BCI) technology. The device is delivered by catheter rather than the open-brain surgeries used by other neurotech developers like Elon Musk’s Neuralink.
Synchron uses the catheter to feed the Stentrode device through a patient’s vein to the blood vessels on the brain (the YouTube video below from 2021 shows the process). Then, th…
[Photo courtesy of Cleveland Clinic]
Cleveland Clinic researchers say they’ve developed a bionic system that takes a big step toward restoring natural arm function for patients with upper limb amputations.Upper-limb amputees often have to constantly watch their prosthetics while using them to make corrections in how much grasping force they use, but Cleveland Clinic said patients testing the new bionic arm system used it with less effort and an easier learning curve.
“Perhaps what we were most excited to learn was that they made judgments, decisions and calculated and corrected for their mistakes like a person without an amputation,” lead investigator Paul Marasco said in a news release. “With the new bionic limb, people behaved like they had a natural hand. Normally, these brain behaviors are very different between people with and without upper limb prosthetics.”
The bionic system combines a neu…